Walton Sara, Fenyi Alexis, Tittle Tyler, Sidransky Ellen, Pal Gian, Choi Solji, Melki Ronald, Killinger Bryan A, Kordower Jeffrey H
ASU-Banner Neurodegenerative Disease Research Center and School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Institut Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Fontenay-Aux-Roses Cedex, France.
bioRxiv. 2023 Aug 25:2023.08.24.554646. doi: 10.1101/2023.08.24.554646.
Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms and alpha-synuclein (αsyn) aggregation in the nervous system. For unclear reasons, PD patients with certain GBA mutations (GBA-PD) have a more aggressive clinical progression. Two testable hypotheses that can potentially account for this phenomenon are that mutations promote αsyn spread or drive the generation of highly pathogenic αsyn polymorphs (i.e., strains). We tested these hypotheses by treating homozygous D409V knockin (KI) mice with human α-syn-preformed fibrils (PFFs) and treating wild-type mice (WT) with several αsyn-PFF polymorphs amplified from brain autopsy samples collected from patients with idiopathic PD and GBA-PD patients with either homozygous or heterozygous mutations. Robust phosphorylated-αsyn (PSER129) positive pathology was observed at the injection site (i.e., the olfactory bulb granular layer) and throughout the brain six months following PFF injection. The PFF seeding efficiency and degree of spread were similar regardless of the mouse genotype or PFF polymorphs. We found that PFFs amplified from the human brain, regardless of patient genotype, were generally more effective seeders than wholly synthetic PFFs (i.e., non-amplified); however, PFF concentration differed between these two studies, and this might also account for the observed differences. To investigate whether the molecular composition of pathology differed between different seeding conditions, we permed Biotinylation by Antibody Recognition on PSER129 (BAR-PSER129). We found that for BAR-PSER129, the endogenous PSER129 pool dominated identified interactions, and thus, very few potential interactions were explicitly identified for seeded pathology. However, we found Dctn2 interaction was shared across all PFF conditions, and Nckap1 and Ap3b2 were unique to PFFs amplified from GBA-PD brains of heterozygous mutation carriers. In conclusion, both the genotype and αsyn strain had little effect on overall seeding efficacy and global PSER129-interactions.
帕金森病(PD)是一种神经退行性疾病,其特征为进行性运动症状以及神经系统中α-突触核蛋白(αsyn)聚集。由于不明原因,某些携带GBA突变的帕金森病患者(GBA-PD)临床进展更为迅速。有两个可验证的假说来解释这一现象,即突变促进αsyn传播或驱动高致病性αsyn多聚体(即毒株)的产生。我们通过用人α-突触核蛋白预形成纤维(PFFs)处理纯合D409V基因敲入(KI)小鼠,并用从散发性帕金森病患者和携带纯合或杂合突变的GBA-PD患者脑尸检样本中扩增的几种αsyn-PFF多聚体处理野生型小鼠(WT)来验证这些假说。在PFF注射后六个月,在注射部位(即嗅球颗粒层)及全脑均观察到强烈的磷酸化α-突触核蛋白(PSER129)阳性病理改变。无论小鼠基因型或PFF多聚体如何,PFF的接种效率和传播程度相似。我们发现,从人脑中扩增的PFF,无论患者基因型如何,通常比完全合成的PFF(即未扩增的)更有效地作为种子;然而,这两项研究中PFF的浓度不同,这也可能解释了观察到的差异。为了研究不同接种条件下病理的分子组成是否不同,我们通过对PSER129进行抗体识别的生物素化(BAR-PSER129)来进行研究。我们发现,对于BAR-PSER129,内源性PSER129库主导了已识别的相互作用,因此,对于接种的病理,明确识别出的潜在相互作用很少。然而,我们发现Dctn2相互作用在所有PFF条件下均存在,而Nckap1和Ap3b2是从杂合突变携带者的GBA-PD脑中扩增的PFF所特有的。总之,基因型和αsyn毒株对总体接种效率和整体PSER129相互作用影响很小。